# Inobrodib

Source: https://onco.cc/drugs/inobrodib/  
OnCo record `inobrodib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Inobrodib is an experimental pill from CellCentric, in phase 3 trials for relapsed or refractory multiple myeloma.

## Summary

Inobrodib (CCS1477) is a small molecule, oral from CellCentric. Blocks the bromodomain of p300 (EP300) and CBP (CREBBP), two proteins that switch on genes, lowering the activity of cancer genes including MYC and IRF4. A phase 3 study with pomalidomide and dexamethasone (NCT07772024, started August 2026) and a phase 2 study (NCT07096778) are recruiting in relapsed or refractory myeloma; earlier studies covered blood cancers (NCT04068597) and advanced solid tumours (NCT03568656). The company says the FDA granted Fast Track and orphan drug designations in relapsed or refractory myeloma.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-11-04
- Also known as: CCS1477
- Tags: pipeline; ctgov-ingest
- Code: CCS1477
- Modality: Small molecule, oral
- Mechanism: Blocks the bromodomain of p300 (EP300) and CBP (CREBBP), two proteins that switch on genes, lowering the activity of cancer genes including MYC and IRF4.

## Sources

- CellCentric clinical trials: https://www.cellcentric.com/clinical-trials/
- CellCentric Series D release, May 2026: https://www.cellcentric.com/press-release/cellcentric-announces-oversubscribed-220-million-series-d-financing-to-advance-pivotal-trials-of-inobrodib-in-multiple-myeloma/
- ClinicalTrials.gov NCT04068597: https://clinicaltrials.gov/study/NCT04068597
- ClinicalTrials.gov NCT07772024: https://clinicaltrials.gov/study/NCT07772024
- ClinicalTrials.gov NCT07096778: https://clinicaltrials.gov/study/NCT07096778
- ClinicalTrials.gov NCT03568656: https://clinicaltrials.gov/study/NCT03568656

## Connected records

- cancers: [Relapsed or refractory multiple myeloma](https://onco.cc/cancers/myeloma-relapsed-refractory/)
- targets: [CREBBP](https://onco.cc/targets/crebbp/), [EP300](https://onco.cc/targets/ep300/)
- companies: [CellCentric](https://onco.cc/companies/cellcentric/)
- trials: [Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma](https://onco.cc/trials/nct07096778/), [Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma](https://onco.cc/trials/nct07772024/), [Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies](https://onco.cc/trials/nct04068597/), [Study to Evaluate CCS1477 in Advanced Tumours](https://onco.cc/trials/nct03568656/)

---
JSON: https://onco.cc/api/v1/entities/inobrodib.json